Drug intelligence / Profile preview

bifidobacterium longum subsp. infantis SINE006

Development stage: Unknown
Lead developer: Chinese PLA General Hospital
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

bifidobacterium longum subsp. infantis SINE006 is a specific probiotic strain of the Bifidobacterium genus. It is currently being evaluated in a Phase 4 clinical trial by the Chinese PLA General Hospital for the treatment of idiopathic short stature (ISS) in children aged 3 to 8 years. The strain is administered orally, typically in combination with organic calcium supplements (such as calcium citrate and fruit-derived calcium). The therapeutic rationale is based on the modulation of the gut microbiota to enhance nutrient absorption and potentially influence the gut-bone axis and systemic growth factors such as insulin-like growth factor 1 (IGF-1), thereby promoting linear growth and bone maturation in children with ISS. The study also explores potential synergy with growth hormone therapy.

Other names: Bifidobacterium longum subsp. infantis SINE006

Beyond the preview

Go deeper on bifidobacterium longum subsp. infantis SINE006.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bifidobacterium longum subsp. infantis SINE006.

Explore the full profile